Dr Reddys Laboratories Ltd
RDY NYSE· Pharmaceutical Preparations
Last close · Oct 30, 2026
$14.17
KIRA · Stoqly’s AI analyst, in plain words
- Dr Reddys Laboratories Ltd had $3.8B of revenue in fiscal 2026, down 1.3% on the year before. Over five years, revenue changed +8.3% a year on average.
- Its operating margin was 15.0%, down 7.0 pts: of every 100 in sales, about 15 is left after running the business.
- Dr Reddys Laboratories Ltd made $485M of net profit in fiscal 2026. From fiscal 2017 to 2026, diluted EPS grew −6.6% a year.
- Free cash flow was $378M in fiscal 2026, 10.0% of revenue.
- Dr Reddys Laboratories Ltd returned $75.3M to shareholders in fiscal 2026, 20% of free cash flow. The diluted share count fell 0.1%.
- Dr Reddys Laboratories Ltd owes $30.2M more than it holds in cash, about 0.0 years of operating profit.
Market cap
$11.8B
P/E
24.4x
Revenue
$3.8B
Net income
$485M
Free cash flow
$378M
Operating margin
15.0%
Dr Reddys Laboratories Ltd in 30 seconds · fiscal 2026
Are sales growing?
−1.3%
No. Sales fell 1.3% last year.
Does it make a profit?
12.8%
Yes. It keeps 12.8% of every sale as profit.
Does profit turn into cash?
10.0%
Partly. 10.0% of sales ends up as free cash.
Is debt under control?
0.0x
Yes. It could repay its debt with 0.0 years of operating profit.
How healthy are the accounts?
4 / 9
Mixed. It passes 4 of 9 health tests.
How is the share priced?
24.4x
One share costs 24.4 times its yearly profit per share.
What Dr Reddys Laboratories Ltd does
No business description yet.
- Fiscal year ends
- March 31, 2026
- Latest annual report
- 20-F · May 29, 2026
- Legal name
- DR REDDYS LABORATORIES LTD
- CIK
- 0001135951
Dr Reddys Laboratories Ltd · RDY · stoqly.net
Results and finances
The last 5 fiscal years. Amounts in USD. Compiled by stoqly.net.
| Fiscal year | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|
| Sales and profit | |||||
| Revenue | $2.9B | $3.1B | $3.4B | $3.8B | $3.8B |
| Revenue growth | 12.6% | 6.4% | 10.2% | 14.2% | −1.3% |
| Net interest income | $0.1M | −$3.1M | $6.8M | −$1.8M | −$0.1M |
| Gross margin | 53.1% | 56.7% | 58.6% | 58.5% | 52.8% |
| Operating margin | 13.7% | 23.2% | 24.3% | 22.1% | 15.0% |
| Net income | $316M | $561M | $673M | $669M | $485M |
| Net margin | 11.0% | 18.3% | 19.9% | 17.4% | 12.8% |
| Diluted EPS | $1.90 | $0.67 | $0.81 | $0.80 | $0.58 |
| Cash | |||||
| Cash from operations | $377M | $733M | $549M | $549M | $642M |
| Capital expenditure | $197M | $141M | $198M | $325M | $264M |
| Free cash flow | $180M | $592M | $351M | $224M | $378M |
| FCF margin | 6.3% | 19.3% | 10.4% | 5.8% | 10.0% |
| Dividends paid | $55.6M | $62.0M | $80.3M | $78.8M | $75.3M |
| Share buybacks | $0.0M | — | — | — | — |
| Share count change | 0.0% | 400.1% | 0.2% | 0.1% | −0.1% |
| Debt and strength | |||||
| Cash and short-term investments | $196M | $70.3M | $85.2M | $172M | $164M |
| Debt incl. finance leases | $89.2M | $74.0M | $87.5M | $102M | $194M |
| Shareholders' equity | $2.5B | $2.8B | $3.4B | $3.9B | $4.0B |
| Net debt / EBITDA | −0.2x | 0.0x | 0.0x | −0.1x | 0.0x |
| Current ratio | 1.9x | 2.4x | 2.6x | 1.9x | 1.8x |
| Interest coverage | 30.8x | 40.0x | 39.6x | 25.4x | 13.5x |
| Returns and quality | |||||
| Return on capital | 12.0% | 18.9% | 18.8% | 16.5% | 10.9% |
| Return on equity | 13.0% | 21.1% | 21.8% | 18.4% | 12.2% |
| Return on tangible equity | 15.1% | 23.5% | 23.4% | 25.4% | 17.6% |
| Piotroski F-score | 7 | 8 | 6 | 3 | 4 |
| Altman Z'' | 6.6 | 8.5 | 8.7 | 6.9 | 6.1 |
Insiders bought, 12 months
$0.0M
0 insiders
Insiders sold, 12 months
$0.0M
0 insiders
Of sales under plans
—
$0.0M
How to read these numbers
- Revenue:
- Total sales reported in the income statement.
- Operating margin:
- Operating income as a share of revenue.
- Net income:
- Profit after all expenses, interest and tax.
- Free cash flow:
- Cash from operations minus capital spending.
- Net debt / EBITDA:
- Years of EBITDA needed to pay off net debt. Below zero means more cash than debt.
- Return on capital:
- After-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
Dr Reddys Laboratories Ltd · RDY · stoqly.net
Charts and comparison
Ten years at a glance, and how it stacks up against similar companies.
Revenue
Net income
Margins, % of revenue
Cash vs debt (incl. leases)
Free cash flow
Dividends and buybacks
KIRA
At $14.17 a share, the company is worth $11.8B: 24.4 times its earnings of the last four quarters.
Compiled and analysed by stoqly.net from SEC EDGAR XBRL filings (CIK 0001135951). Latest version: stoqly.net/companies/rdy. Data updated November 1, 2026. Filed in INR under IFRS and converted to US$: income and cash-flow lines at each period's average exchange rate, balance-sheet lines at the period-end rate. For information only — not investment advice. Check the original filings before relying on any figure.